生物制药公司Viking Therapeutics, Inc.(VKTX)今日股价大涨5.77%,报收于65.15美元,引起市场广泛关注。
数据显示,Viking Therapeutics主攻代谢和内分泌疾病领域,其三款临床产品VK2809、VK5211、VK0214进展顺利,为公司未来发展注入动力。其中,VK2809和VK0214是甲状腺激素受体β亚型选择性激动剂,已处于晚期临床试验阶段,有望成为全新疗法上市。VK5211则是一种潜力巨大的雄激素受体调节剂,目前处于临床一期试验。
此外,机构分析人士普遍看好公司前景,所有参与评级的14家券商均给予了买入评级,这进一步增强了投资者的信心。尽管最新财报显示公司暂无营收,但专注前景产品开发,未来潜力可期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.